Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-16), Oncopeptides AB's 14-Day RSI is 46.30.
The industry rank for Oncopeptides AB's 14-Day RSI or its related term are showing as below:
FRA:OND's 14-Day RSI is ranked better than 53.69% of 1423
companies
in the Biotechnology industry
Industry Median: 47.36
vs FRA:OND: 46.30
Oncopeptides AB (FRA:OND) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Oncopeptides AB 14-Day RSI Related Terms
FRA:OND vs VRTX, REGN, ALNY: 14-Day RSI Comparison
For the Biotechnology subindustry, Oncopeptides AB's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncopeptides AB 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncopeptides AB's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Oncopeptides AB's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncopeptides AB (FRA:OND) has a 14-Day RSI of 46.30 as of Jul. 16, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Oncopeptides AB and its competitors. According to the industry distribution chart, Oncopeptides AB ranks #659 out of 1423 companies in the Biotechnology industry, placing it in the top 46.3%.
Is Oncopeptides AB's 14-Day RSI too high?
Oncopeptides AB's current 14-Day RSI is 46.30. The Biotechnology industry median 14-Day RSI is 47.36. Oncopeptides AB's value of 46.30 is 2.2% below this industry median. Based on the distribution chart, Oncopeptides AB ranks #659 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oncopeptides AB has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncopeptides AB ranks #659 out of 1423 companies for 14-Day RSI. This puts Oncopeptides AB in the upper half of its industry. The industry median 14-Day RSI is 47.36. Oncopeptides AB's value of 46.30 is 2.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 47.36, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncopeptides AB's current 14-Day RSI of 46.30 is 2.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Oncopeptides AB and its competitors. For the Biotechnology industry, the median 14-Day RSI is 47.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncopeptides AB's current 14-Day RSI is 46.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (FRA:OND) is currently considered Possible Value Trap. The stock's GF Value™ is €0.39, compared to a current price of €0.14 — trading 63.3% below its estimated fair value. The current 14-Day RSI is 46.30 and 2.2% below the Biotechnology industry median of 47.36. Oncopeptides AB's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Oncopeptides AB (FRA:OND), the current 14-Day RSI is 46.30 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncopeptides AB (FRA:OND) Overvalued in 2026?
Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued.
The current stock price of €0.14 is trading 63.3% below its estimated GF Value™ of €0.39.
GuruFocus considers Oncopeptides AB to be Possible Value Trap.
Key valuation signals for FRA:OND:
14-Day RSI: 46.30
GF Value™: €0.39 vs. price of €0.14 (63.3% below fair value)
Industry Position: 2.2% below the Biotechnology median (#659 of 1423)
No single metric tells the full story. See the FRA:OND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
34GF Score
Get the complete analysis for FRA:OND
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OND has been successfully added to your 
